{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:37:07Z","timestamp":1786117027503,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022217","name":"Flinders Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biopha.2026.119759","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:33:46Z","timestamp":1783690426000},"page":"119759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["DDAH1 and DDAH2 drive vasculogenic mimicry and more aggressive phenotypes in triple negative breast cancer cells"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-7352","authenticated-orcid":false,"given":"Jai","family":"Meyers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lashika","family":"Weerakoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4933-9825","authenticated-orcid":false,"given":"Vinitha","family":"Ragavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Jarzebska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman N.","family":"Rodionov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8699-1412","authenticated-orcid":false,"given":"Arduino A.","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-Ann","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-2602","authenticated-orcid":false,"given":"Sara","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2026.119759_bib1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/imj.13628","article-title":"Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney","volume":"48","author":"Naher","year":"2018","journal-title":"Intern. Med. J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119759_bib2","doi-asserted-by":"crossref","first-page":"21608","DOI":"10.1038\/s41598-021-01116-6","article-title":"Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119759_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1405491","article-title":"Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies","volume":"14","author":"Xiong","year":"2024","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119759_bib4","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"issue":"Pt 2","key":"10.1016\/j.biopha.2026.119759_bib5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.semcancer.2022.03.001","article-title":"Nano-targeting vascular remodeling in cancer: Recent developments and future directions","volume":"86","author":"Giordo","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119759_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2026.119759_bib7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdp062","article-title":"Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer","volume":"20","author":"Linderholm","year":"2009","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119759_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0002-9440(10)64739-6","article-title":"Vasculogenic Mimicry and Tumor Angiogenesis","volume":"156","author":"Folberg","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2026.119759_bib9","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2147\/CMAR.S164675","article-title":"Overview of advances in vasculogenic mimicry - a potential target for tumor therapy","volume":"10","author":"Ge","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119759_bib10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1042\/BST0371243","article-title":"The DDAH\/ADMA pathway in the control of endothelial cell migration and angiogenesis","volume":"37","author":"Fiedler","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.biopha.2026.119759_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118013","article-title":"Current knowledge on the mechanisms underpinning vasculogenic mimicry in triple negative breast cancer and the emerging role of nitric oxide","volume":"186","author":"Alemu","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.biopha.2026.119759_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0008-6363(99)00115-7","article-title":"and B. Mayer, Enzymatic function of nitric oxide synthases.","volume":"43","author":"Andrew","year":"1999","journal-title":"Cardiovasc. Res."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2026.119759_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1042\/bj3430209","article-title":"Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases","volume":"343","author":"Leiper","year":"1999","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119759_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/geno.2000.6262","article-title":"Chromosomal Localization, Gene Structure, and Expression Pattern of DDAH1: Comparison with DDAH2 and Implications for Evolutionary Origins","volume":"68","author":"Tran","year":"2000","journal-title":"Genomics"},{"issue":"5","key":"10.1016\/j.biopha.2026.119759_bib15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.str.2006.03.006","article-title":"Structure of the Mammalian NOS Regulator Dimethylarginine Dimethylaminohydrolase: A Basis for the Design of Specific Inhibitors","volume":"14","author":"Frey","year":"2006","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.biopha.2026.119759_bib16","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1038\/s41467-023-38467-9","article-title":"A multicentric consortium study demonstrates that dimethylarginine dimethylaminohydrolase 2 is not a dimethylarginine dimethylaminohydrolase","volume":"14","author":"Ragavan","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119759_bib17","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3389\/fonc.2019.01455","article-title":"Inhibition of Dimethylarginine Dimethylaminohydrolase (DDAH) Enzymes as an Emerging Therapeutic Strategy to Target Angiogenesis and Vasculogenic Mimicry in Cancer","volume":"9","author":"Hulin","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119759_bib18","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1161\/01.ATV.0000219615.88323.b4","article-title":"Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells","volume":"26","author":"Hasegawa","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2026.119759_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.exer.2016.05.007","article-title":"Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis","volume":"147","author":"Lange","year":"2016","journal-title":"Exp. Eye Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119759_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00428-015-1863-z","article-title":"Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma","volume":"468","author":"Shiozawa","year":"2016","journal-title":"Virchows Arch."},{"issue":"678","key":"10.1016\/j.biopha.2026.119759_bib21","doi-asserted-by":"crossref","first-page":"eabc7931","DOI":"10.1126\/scisignal.abc7931","article-title":"DDAH2 suppresses RLR-MAVS\u2013mediated innate antiviral immunity by stimulating nitric oxide\u2013activated, Drp1-induced mitochondrial fission","volume":"14","author":"Huang","year":"2021","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.biopha.2026.119759_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/art.30652","article-title":"Dimethylarginine dimethylaminohydrolase 2, a newly identified mitochondrial protein modulating nitric oxide synthesis in normal human chondrocytes","volume":"64","author":"Cillero-Pastor","year":"2012","journal-title":"Arthritis & Rheum."},{"issue":"6","key":"10.1016\/j.biopha.2026.119759_bib23","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1096\/fj.12-226092","article-title":"The hydrolase DDAH2 enhances pancreatic insulin secretion by transcriptional regulation of secretagogin through a Sirt1-dependent mechanism in mice.","volume":"27","author":"Hasegawa","year":"2013","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.biopha.2026.119759_bib24","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/ATVBAHA.115.305278","article-title":"Dimethylarginine Dimethylaminohydrolase 2 Regulates Nitric Oxide Synthesis and Hemodynamics and Determines Outcome in Polymicrobial Sepsis","volume":"35","author":"Lambden","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2026.119759_bib25","series-title":"Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders","first-page":"21","article-title":"Chapter 2 - The emerging role of dimethylarginine dimethylaminohydrolase 2 in regulating vasculogenic mimicry in cancer","author":"Mangoni","year":"2025"},{"issue":"1","key":"10.1016\/j.biopha.2026.119759_bib26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/s12885-025-13908-4","article-title":"L-arginine dependence of breast cancer \u2013 molecular subtypes matter","volume":"25","author":"Hannemann","year":"2025","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119759_bib27","doi-asserted-by":"crossref","first-page":"13996","DOI":"10.1038\/s41598-017-14454-1","article-title":"MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1","volume":"7","author":"Hulin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119759_bib28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.biopha.2018.12.117","article-title":"Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro","volume":"111","author":"Hulin","year":"2019","journal-title":"Biomed. & Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2026.119759_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-020-01288-1","article-title":"Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments","volume":"20","author":"Wei","year":"2021","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119759_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"npj Breast Cancer"},{"issue":"16","key":"10.1016\/j.biopha.2026.119759_bib31","first-page":"4960","article-title":"Effects of Overexpression of Dimethylarginine Dimethylaminohydrolase on Tumor Angiogenesis Assessed by Susceptibility Magnetic Resonance Imaging","volume":"63","author":"Kostourou","year":"2003","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119759_bib32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.2904","article-title":"Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas","volume":"225","author":"Boult","year":"2011","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119759_bib33","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0006-291X(03)01507-9","article-title":"Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype","volume":"308","author":"Smith","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2026.119759_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/dmrr.939","article-title":"Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells","volume":"25","author":"Xiao","year":"2009","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"10.1016\/j.biopha.2026.119759_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3909102","article-title":"VEGF Induce Vasculogenic Mimicry of Choroidal Melanoma through the PI3k Signal Pathway","volume":"2019","author":"Xu","year":"2019","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.biopha.2026.119759_bib36","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1161\/ATVBAHA.110.215640","article-title":"Dimethylarginine Dimethylaminohydrolase 1 Modulates Endothelial Cell Growth Through Nitric Oxide and Akt","volume":"31","author":"Zhang","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119759_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10456-017-9587-0","article-title":"Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA)","volume":"21","author":"Reddy","year":"2018","journal-title":"Angiogenesis"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600795X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600795X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:11:19Z","timestamp":1786021879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222600795X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S075333222600795X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119759","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DDAH1 and DDAH2 drive vasculogenic mimicry and more aggressive phenotypes in triple negative breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119759"}}